PKC Inhibitors
1 drugsAbout PKC
Protein kinase C (PKC) is a family of serine/threonine kinases involved in cell growth, differentiation, apoptosis, and inflammation. These enzymes play a crucial role in various cellular signaling pathways.
PKC's role in cell signaling makes it a compelling target for drug development, though there is currently no genetic evidence directly linking PKC to specific diseases.
PKC is targeted by one FDA-approved small molecule drug, RYDAPT (Novartis), which has four indications in oncology.
Strategic Insights
ℹ️ How we calculate- White space opportunity in FLT3-mutated Acute Myeloid Leukemia with only 1 trials.
- phase2 represents biological uncertainty with 50% completion.
Top Drugs
Novartis is the only company with an approved drug targeting PKC.
Low competition suggests an opportunity for new entrants, but also highlights potential challenges in the target's druggability.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets PKC, using small molecule modality.
Explore opportunities for novel modalities like antibodies or PROTACs to differentiate from existing therapies.
Clinical Trials 58 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 23 | 16 | 4 | 3 | 80% |
| Phase 2 | 19 | 8 | 6 | 5 | 57% |
| Phase 3 | 8 | 6 | 0 | 2 | 100% |
| Phase 4 | 8 | 3 | 2 | 3 | 60% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved PKC drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting PKC. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Drug Approval Timeline (2017 - 2017)
The first and most recent drug approval for PKC was RYDAPT in 2017.
The single approval in 2017 indicates a potentially saturated market or challenges in developing successful PKC-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 36 clinical trials targeting PKC.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities